Skip to main content
main-content

The independent medical news service

14-10-2019 | Oncology | News | Article

SORCE rules out adjuvant sorafenib for RCC

Sorafenib should not be used in the adjuvant setting in patients with resected renal cell carcinoma at intermediate or high risk of relapse, says the SORCE research team.

08-10-2019 | Oncology | News | Article

JAVELIN Renal 101 subanalyses add to evidence for avelumab plus axitinib

Findings from the JAVELIN Renal 101 trial of patients with advanced renal cell carcinoma suggest front-line use of avelumab plus axitinib is superior to sunitinib for patients with sarcomatoid histology and for those who did not undergo upfront cytoreductive nephrectomy.

25-09-2019 | Oncology | News | Article

Avelumab indication extended in Europe to advanced RCC

Find out more here

02-09-2019 | Oncology | Main feed | Article

Elevated cardiovascular risk seen in survivors of most common cancers

Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.

21-08-2019 | Oncology | News | Article

Long-term benefit of nivolumab plus ipilimumab shown in advanced RCC

Patients with previously untreated advanced renal cell carcinoma derive greater long-term survival benefits from nivolumab plus ipilimumab than from sunitinib, according to the latest results from the phase III CheckMate 214 trial.

31-07-2019 | Oncology | News | Article

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

Image Credits